BTAI BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (BTAI) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.35 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.2% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.
Sector
Healthcare
Industry
Biotechnology